NORDIC | IMPACT – Do you dare taking a big bite? Food & Beverage sector in focus. (week 48)
In the past week, the Nordic impact sectors had mixed results once again. The sector Power2X & Fuel Cells came
1. december 2023
In the past week, the Nordic impact sectors had mixed results once again. The sector Power2X & Fuel Cells came
In the past week, the Nordic impact sectors had mixed results. Energy Production & Storage performed the best, while other
In the past week, the Nordic impact sectors had another well performing week. Only Food & Beverages delivered a negative
In the past week, the Nordic impact stocks made another small comeback in a challenging year. Every sector delivered a
In the past week, the Nordic impact stocks made a small comeback after a difficult year. The Energy Production and
Curasight har fået positive studieresultater i fase 2 studie med uTRACE mod aggressiv hjernekræft, der dels validerer teknologien og åbner
I maj måned opsagde nuværende CEO i Ekobot sin stilling, hvilket har skabt uro og en faldende aktiekurs. Selskabet har
Mdundo guider om kraftig vækst for regnskabsåret 2023/24, og har fortsat kurs mod sine langsigtede målsætninger i 2025. Mon det
Positive prækliniske studieresultater (i dyr) for uTREAT giver medvind til Curasights platform til behandling af det over EUR 5 mia.
Biosergen påviste positive fase I resultater for BSG005 i Q1. Allerede i Q2 igangsætter selskabet et fase 2 studie, der
Kapital Partner udfører eller har inden for de seneste 12 måneder udført corporate finance, market relations, investor relations, Certified Adviser eller andre rådgivningsaktiviteter for følgende børsnoterede selskaber: CS Medica, EKOBOT AB, Biotech, Ensurge, Lifecare AS, NORD.investments, Biosergen, Hypefactors, Curasight, Re-Match, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.